The FEMME trial 's primary outcome is the quality of life women with symptomatic uterine fibroids experience two years after they have been treated with either UAE or myomectomy , as measured by the disease-specific Uterine Fibroid Symptom Quality-of-Life ( UFS-QoL ) questionnaire .